Compare US Bancorp (USB) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
US Bancorp vs GeneDx Holdings Corp — how do they compare? US Bancorp trades at $57.15 (market cap $87.52B), while GeneDx Holdings Corp trades at $67.6 (market cap $2.04B). The key difference: US Bancorp is far larger — about 42.9× GeneDx Holdings Corp's market cap, and US Bancorp pays a 3.85% dividend while GeneDx Holdings Corp pays none. Which is the better fit depends on your goals — on Pluang, investors hold US Bancorp for 97 Days and GeneDx Holdings Corp for 19 Days on average.
| USB | WGS | |
|---|---|---|
Market Cap | $87.52B | $2.04B |
Volume | 9,184,647 | 659,215 |
Sector | Financials | Health |
52-Week High | $65.42 | $167.51 |
52-Week Low | $45.28 | $34.51 |
Typical Hold Time | 97 Days | 19 Days |
Enterprise Value | $117.01B | $2.08B |
Dividend Yield | 3.85% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
U.S. Bancorp (USB) trades at $56.17, down 1.95% on the day, with a bearish technical outlook despite strong fundamentals. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. USB maintains robust profitability with a 27.61% net income margin and attractive valuation metrics including a P/E of 11.21. Recent news highlights dividend increases and positive business momentum in payments and capital markets.
The stock presents a compelling value opportunity with analyst consensus target of $69.94 (24.5% upside), though technical indicators signal near-term caution. Key risks include interest rate sensitivity and regulatory changes, while institutional sentiment remains positive with 51% buy ratings. The upcoming Q3 earnings report will be critical for confirming the positive fundamental trajectory.
GeneDx (WGS) trades at $68.53, down 4.18% today amid bearish technical signals despite recent positive earnings surprises. The stock shows mixed fundamentals with strong revenue growth to $454M in 2026 but negative profitability metrics including -23.4% net margin. Recent developments include new genomic testing products and hospital partnerships, while analyst consensus remains strongly bullish with a $81 price target representing 18% upside potential.
The investment case balances strong analyst support and genomic testing market growth against persistent profitability challenges and negative cash flow trends. Key catalysts include Q3 2026 earnings due soon and continued execution on operational improvements, while risks center on margin recovery timeline and competitive pressures in the rapidly evolving genomics space.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About US Bancorp
As a diversified financial-services provider, U.S. Bancorp is one of the nation's largest regional banks, with branches in well over 20 states, primarily in the Western and Midwestern United States. The bank offers many services, including retail banking, commercial banking, trust and wealth services, credit cards, mortgages, and other payments capabilities.
Read more on USB →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
